Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
June 04, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidateLate-breaking abstract selected for oral presentation on...
Global Cell Therapy Bioprocessing Market Report 2021-2028: Digital Biomanufacturing to Gain Prominence
June 03, 2021 05:58 ET
|
Research and Markets
Dublin, June 03, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Cell Type, End User, and Geography" report has...
Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 06, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND...
Outlook on the Cell Therapy Global Market to 2027 - by Therapy Type, Product, Technology, Application, End-user and Geography
March 31, 2021 05:18 ET
|
Research and Markets
Dublin, March 31, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy Type; Product; Technology; Application; End User, and Geography"...
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
March 30, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Global Precision Medicine Market (2021 to 2028) - Demand for Preventive Care Presents Opportunities
March 25, 2021 08:13 ET
|
Research and Markets
Dublin, March 25, 2021 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The publisher predicts that the global market...
Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
March 25, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at...
North America Digital Genome Market Report 2021: Continuous Funding by the Manufacturers and Government in the Field of Genomics - Forecast to 2028
March 15, 2021 06:03 ET
|
Research and Markets
Dublin, March 15, 2021 (GLOBE NEWSWIRE) -- The "North America Digital Genome Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. North America market for digital genome is...
Outlook on the Cell Therapy Biomanufacturing Global Market to 2025 - by Product Type, Application and Region
February 22, 2021 06:48 ET
|
Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Biomanufacturing: Global Markets" report has been added to ResearchAndMarkets.com's offering. This research report presents an in-depth...
Global Gene Therapy Market Outlook to 2030 - by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration and Key Geographical Regions
February 15, 2021 07:03 ET
|
Research and Markets
Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key...